Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LB PHARMACEUTICALS INCLBRX · Entity 4678 | Senior Vice President, Finance | September 10, 2025 | September 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LB PHARMACEUTICALS INC
Report date September 10, 2025 · Filed September 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.15 · Expires 2028-11-13 | Direct | 0 |
Reported balance
After 2025-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-10 · Disposition to issuer · Disposed 3,944 · Balance 0 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2028-11-13 | Direct | 3,944 |
Reported balance
After 2025-09-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-09-10 · Grant · Acquired 3,944 · Balance 3,944 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.72 · Expires 2029-12-22 | Direct | 0 |
Reported balance
After 2025-09-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-09-10 · Disposition to issuer · Disposed 896 · Balance 0 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-12-22 | Direct | 896 |
Reported balance
After 2025-09-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-09-10 · Grant · Acquired 896 · Balance 896 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.72 · Expires 2030-08-30 | Direct | 0 |
Reported balance
After 2025-09-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-09-10 · Disposition to issuer · Disposed 1,255 · Balance 0 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2030-08-30 | Direct | 1,255 |
Reported balance
After 2025-09-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-09-10 · Grant · Acquired 1,255 · Balance 1,255 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.84 · Expires 2033-08-24 | Direct | 0 |
Reported balance
After 2025-09-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-09-10 · Disposition to issuer · Disposed 14,343 · Balance 0 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F3: One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2033-08-24 | Direct | 14,343 |
Reported balance
After 2025-09-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-09-10 · Grant · Acquired 14,343 · Balance 14,343 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F3: One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.84 · Expires 2034-06-26 | Direct | 0 |
Reported balance
After 2025-09-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-09-10 · Disposition to issuer · Disposed 7,171 · Balance 0 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F4: One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2034-06-26 | Direct | 7,171 |
Reported balance
After 2025-09-10 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-09-10 · Grant · Acquired 7,171 · Balance 7,171 F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F4: One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2035-09-09 | Direct | 90,525 |
Reported balance
After 2025-09-10 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-09-10 · Grant · Acquired 90,525 · Balance 90,525 F5: One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately exercisable.
F2: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.
F3: One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F4: One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F5: One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2025 Filed Sep 30, 2025 00:16 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantEmployee Stock Option (Right to Buy) · Derivative | 90,525 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001304340-25-000006 · form4-09302025_120930.xml · derivative · entry 11 PANOFF MARC L · CIK 0001304340 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,525 Underlying: Common Stock · 90,525 shares Expires 2035-09-09 F5 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 30, 2025 00:16 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,171 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001304340-25-000006 · form4-09302025_120930.xml · derivative · entry 10 PANOFF MARC L · CIK 0001304340 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,171 Underlying: Common Stock · 7,171 shares Expires 2034-06-26 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F4 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 30, 2025 00:16 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 7,171 | Not disclosed Strike: $41.84 | Not disclosed |
DisclosureSEC source: 0001304340-25-000006 · form4-09302025_120930.xml · derivative · entry 9 PANOFF MARC L · CIK 0001304340 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,171 shares Expires 2034-06-26 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F4 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 30, 2025 00:16 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,343 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001304340-25-000006 · form4-09302025_120930.xml · derivative · entry 8 PANOFF MARC L · CIK 0001304340 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,343 Underlying: Common Stock · 14,343 shares Expires 2033-08-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 30, 2025 00:16 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 14,343 | Not disclosed Strike: $41.84 | Not disclosed |
DisclosureSEC source: 0001304340-25-000006 · form4-09302025_120930.xml · derivative · entry 7 PANOFF MARC L · CIK 0001304340 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,343 shares Expires 2033-08-24 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 30, 2025 00:16 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,255 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001304340-25-000006 · form4-09302025_120930.xml · derivative · entry 6 PANOFF MARC L · CIK 0001304340 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,255 Underlying: Common Stock · 1,255 shares Expires 2030-08-30 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 30, 2025 00:16 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 1,255 | Not disclosed Strike: $69.72 | Not disclosed |
DisclosureSEC source: 0001304340-25-000006 · form4-09302025_120930.xml · derivative · entry 5 PANOFF MARC L · CIK 0001304340 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,255 shares Expires 2030-08-30 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 30, 2025 00:16 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantEmployee Stock Option (Right to Buy) · Derivative | 896 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001304340-25-000006 · form4-09302025_120930.xml · derivative · entry 4 PANOFF MARC L · CIK 0001304340 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 896 Underlying: Common Stock · 896 shares Expires 2029-12-22 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 30, 2025 00:16 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 896 | Not disclosed Strike: $69.72 | Not disclosed |
DisclosureSEC source: 0001304340-25-000006 · form4-09302025_120930.xml · derivative · entry 3 PANOFF MARC L · CIK 0001304340 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 896 shares Expires 2029-12-22 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 30, 2025 00:16 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,944 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001304340-25-000006 · form4-09302025_120930.xml · derivative · entry 2 PANOFF MARC L · CIK 0001304340 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,944 Underlying: Common Stock · 3,944 shares Expires 2028-11-13 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 10, 2025 Filed Sep 30, 2025 00:16 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 3,944 | Not disclosed Strike: $64.15 | Not disclosed |
DisclosureSEC source: 0001304340-25-000006 · form4-09302025_120930.xml · derivative · entry 1 PANOFF MARC L · CIK 0001304340 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,944 shares Expires 2028-11-13 F2 · price: The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.